Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis David J. StewartG. Peter RaaphorstArthur R. Beaubien Lead Article Pages: 115 - 130
Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor Robert T. DorrKaterina DvorakovaG. Robert Pettit Preclinical Studies Pages: 131 - 137
Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives Marina RipamontiLaura CapolongoAntonino Suarato Preclinical Studies Pages: 139 - 146
Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein Saïk UrienJérôme BarréJean-Paul Tillement Preclinical Studies Pages: 147 - 151
Efficacy of 5′-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro Irene DjuandaHenrik DepenbrockAxel-R. Hanauske Preclinical Studies Pages: 153 - 159
Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents Michael J. KelnerTrevor C. McMorrisRaymond Taetle Preclinical Studies Pages: 161 - 167
In vitro cytotoxicity of S16020-2, a new olivacine derivative Stéphane LéonceValérie PerezGhanem Atassi Preclinical Studies Pages: 169 - 180
Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9 Jantine D. Jonkman-de VriesJ. Jantina Kettenes-van den BoschJos H. Beijnen Preclinical Studies Pages: 181 - 191
Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer Slawomir Wojtowicz-PragaJennifer LowMichael J. Hawkins OriginalPaper Pages: 193 - 202
Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group Peter ForsythGreg CairncrossElisabeth Eisenhauer OriginalPaper Pages: 203 - 206
A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma Kathy D. MillerPatrick J. LoehrerJoanne Mortimer OriginalPaper Pages: 207 - 212
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma S. L. AllenL. P. SchacterS. Huybensz OriginalPaper Pages: 213 - 217
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma Paul V. WoolleyCarolyn J. SchultzJoseph J. McPhillips OriginalPaper Pages: 219 - 222
Phase II study of Mitonafide in advanced and relapsed colorectal cancer Albert AbadCristina GrávalosMiguel Martin OriginalPaper Pages: 223 - 225
Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma Jinee RizzoAlexandra M. LevineJohn G. Kuhn OriginalPaper Pages: 227 - 234
Octreotide as first-line treatment for women with metastatic breast cancer James N. IngleCarl G. KardinalAlan K. Hatfield Brief Report Pages: 235 - 237